Skip to main content

Table 4 Efficacy of SCT200

From: Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

Dose

0.5 mg/kg

QW

1.0 mg/kg

QW

2.0 mg/kg

QW

4.0 mg/kg

QW

6.0 mg/kg

QW

6.0 mg/kg

Q2W

8.0 mg/kg

Q2W

9.0 mg/kg

QW

12.0 mg/kg

QW

15.0 mg/kg

QW

Overall

(N=3)

(N=3)

(N=3)

(N=4)

(n=28)

(n=3)

(n=3)

(n=3)

(n=3)

(n=3)

(n=56)

Efficacy, n

CR

0

0

0

0

0

0

0

0

0

0

0

PR

0

0

0

0

12

2

0

0

2

1

17

SD

0

0

1

2

12

1

2

2

1

1

22

PD

3

2

2

2

3

0

1

1

0

1

15

NE

0

1

0

0

1

0

0

0

0

0

2

ORR (CR/PR), % (95% CI)

0 (0.0–70.8)

0 (0.0–70.8)

0 (0.0–70.8)

0 (0.0–60.2)

42.9 (24.5–62.8)

66.7 (9.4–99.2)

0.0 (0.0–70.8)

0.0 (0.0–70.8)

66.7 (9.4–99.2)

33.3 (0.8–90.6)

30.4 (18.8–44.1)

DCR (CR/PR/SD), % (95% CI)

0 (0.0–70.8)

0 (0.0–70.8)

33.3 (0.8–90.6)

50 (6.8– 93.2)

85.7 (67.3–96.0)

100.0 (29.2–100.0)

66.7 (9.4–99.2)

66.7 (9.4–99.2)

100.0 (29.2–100.0)

66.7 (9.4–99.2)

69.6 (55.9–81.2)

  1. CI Confidence interval, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, NE Non-evaluable, QW Quaque week, Q2W Quaque 2 week, ORR Objective response rate, DCR Disease control rate